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Abstract
Schimke immuno-osseous dysplasia (OMIM 242900) is an
uncommon autosomal-recessive multisystem disease caused by
mutations in SMARCAL1 (swi/snf-related, matrix-associated, actin-
dependent regulator of chromatin, subfamily a-like 1), a gene
encoding a putative chromatin remodeling protein. Neurologic
manifestations identiﬁed to date relate to enhanced atherosclerosis
and cerebrovascular disease. Based on a clinical survey, we
determined that half of Schimke immuno-osseous dysplasia patients
have a small head circumference, and 15% have social, language,
motor, or cognitive abnormalities. Postmortem examination of 2
Schimke immuno-osseous dysplasia patients showed low brain
weights and subtle brain histologic abnormalities suggestive of
perturbed neuron-glial migration such as heterotopia, irregular
cortical thickness, incomplete gyral formation, and poor deﬁnition
of cortical layers. We found that SMARCAL1 is highly expressed in
the developing and adult mouse and human brain, including neural
precursors and neuronal lineage cells. These observations suggest
that SMARCAL1 deﬁciency may inﬂuence brain development and
function in addition to its previously recognized effect on cerebral
circulation.
Key Words: Immunodeﬁciency, Microcephaly, Neural stem cell,
Neuronal migration, Renal disease, Skeletal dysplasia
INTRODUCTION
Neurons of the central nervous system (CNS) originate
from the neural precursors within the neuroepithelium sur-
rounding the developing ventricles. The neuronal or glial
destiny of the precursors is partly dependent on the number of
preceding cell cycles (1). Neurons arise more frequently when
the precursor has completed fewer cell divisions, whereas glia
arise more frequently when the precursor has completed a
higher number of cell divisions (2, 3). Additionally, sym-
metric or asymmetric cell division determines whether both
progeny of a neural precursor remain precursors or whether 1
daughter cell will become a neuron or glia and 1 daughter cell
will remain as a neural precursor (2, 4).
The migration of neuronal precursors from the neuro-
epithelium is carefully choreographed to form cortical layers
2 to 6 (5). A major population of neuronal precursors is
guided to the cortex by climbing radial glial ﬁbers (6). The
cerebral cortex is formed by an inside-out migration; thus,
neurons generated early in cortical development occupy more
proximal or internal layers, and those generated later occupy
more distal or external layers (7). Neuronal migration can be
divided into several key stages according to mutations
identiﬁed in human diseases: initiation of migration, effective
migration, and penetration of the subplate (8).
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Schimke immuno-osseous dysplasia (SIOD; OMIM
242900) is an uncommon autosomal-recessive multisystem
disease caused by mutations in the putative chromatin
remodeling protein SMARCAL1 (swi/snf-related, matrix-
associated, actin-dependent regulator of chromatin, subfamily
a-like 1). Clinical studies of SIOD have suggested that this
multisystem disease is the result of a defect in selective cellular
proliferation because its phenotype includes short stature from
impaired chondrogenesis, T-cell deﬁciency from impaired
T-cell proliferation, azoospermia from testicular hypoplasia,
and, occasionally, bone marrow failure from impaired blood
precursor proliferation (9, 10). Other aspects of SIOD are also
consistent with impaired differentiation and tissue mainte-
nance and include progressive atherosclerosis leading to
cerebral ischemic lesions, renal failure from focal segmental
glomerulosclerosis, and fatty inﬁltration of the right ventricu-
lar wall resembling an arrhythmogenic right ventricular
cardiomyopathy (9, 10). SMARCAL1 is homologous to the
SNF2 chromatin remodeling proteins and the SF2 family of
helicases (11, 12). In vitro, SMARCAL1 has DNA-dependent
adenosine triphosphatase activity and binds nucleosomes
(12, 13), but its in vivo function has not been deﬁned.
In this study, we investigated possible roles of
SMARCAL1 in CNS development by characterizing non-
ischemic brain pathology in autopsy tissue from 2 patients
with SIOD. Both patients had a reduced brain weight and
subtle microscopic ﬁndings suggestive of malformative
processes. To explore the possible implications of these
developmental brain lesions, we examined the records of 33
SIOD patients with SMARCAL1 mutations for evidence of
decreased brain size, psychomotor delay, and seizures. We
found that nearly half of SIOD patients had a head circum-
ference at least 2 standard deviations less than the mean, and
approximately 15% had social, language, motor, or cognitive
abnormalities. To determine whether these functional and
morphologic problems might correlate with disordered brain
development in SIOD, we analyzed SMARCAL1 expression
in human and murine neural development. SMARCAL1 was
found to be highly expressed in human and mouse neural
precursors and neurons. Thus, the loss of functional SMAR-
CAL1 may affect the regulation of brain development and
cause cerebrovascular ischemia in SIOD.
MATERIALS AND METHODS
Human Subjects
Patients referred to this study gave informed consent
approved by the institutional review board of Baylor College
of Medicine (Houston, TX) or the Hospital for Sick Children
(Toronto, Ontario, Canada). The clinical data for patients
were obtained from questionnaires completed by the respon-
sible physician and from medical records and summaries
provided by that physician. Postmortem tissue samples were
obtained from patients whose families gave informed consent
approved by the institutional review board of Baylor College
of Medicine.
Human brain tissue for Western and Northern analyses
was obtained from the Birth Defects Laboratory (University of
Washington, Seattle, WA). Human brain tissue for immuno-
histochemical and immunoﬂuorescent analyses was obtained
from autopsy specimens of unaffected individuals aged 6
gestational weeks (GW) to 61 years; these were obtained after
informed consent approved by the institutional review board of
Baylor College of Medicine and Texas Children_s Hospital.
The autopsies were performed within 24 hours of death.
Tissue Pathology and Expression Analyses
Two to 4 investigators who were blinded to the source
of the tissue samples determined the pathologic ﬁndings,
identiﬁed immunohistochemically positive cells, and scored
the numbers of immunohistochemically positive cells. The
assessments of human tissue were done in both SIOD
patients and in human control samples as described in the
Results section. The assessment of Smarcal1 expression in
mouse tissue was done using animals of 3 different genetic
backgrounds: 129SvEv, C57BL6, and ICR.
Human and Mouse Neurosphere Culture
All experiments using human neural precursor cells
that were derived from human fetal neural tissue aged 7 to 10
GW were performed at Keio University with the approval of
the institutional review board and in agreement with the
ethical guidelines of the ethical committees of Osaka
National Hospital and Keio University. Tissue procurement
was in accordance with the Declaration of Helsinki and in
agreement with the ethical guidelines of the Japan Society of
Obstetrics and Gynecology.
Human Neurosphere Culture
Human neural precursor cell cultures were established
using the neurosphere method (14). The cells used had been
cultured for more than 1 year. Cells were cultured in
Dulbecco_s modiﬁed Eagle_s medium (DMEM)/F12 serum-
free medium complemented with B27 supplement (Gibco,
Grand Island, NY), recombinant human epidermal growth
factor (20 ng/ml; R&D, Minneapolis, MN), recombinant
human basic ﬁbroblast growth factor (20 ng/ml; Genzyme
TECHINE, Minneapolis, MN), leukemia inhibiting factor
(Chemicon, Temecula, CA), and heparin (Sigma, St. Louis,
MO). For differentiation, the cells were dissociated with
0.05% trypsin (Gibco) for 20 minutes at 37-C and plated on
polyornithine- and laminin-coated glass coverslips (Sigma),
followed by incubation with DMEM/F12 medium with either
B27 supplement or 10% fetal bovine serum for 6 days.
Mouse Neurosphere Culture
Murine neural precursor cells were established from
E12.5 and E14.5 ICR embryos using the neurosphere method
(15). Brieﬂy, embryos were removed from the uterus of
timed pregnant mice and placed in a Petri dish containing
Hanks_ balanced salt solution (Gibco). The mouse tele-
ncephalon was freed from meninges, and the cells were
dissociated by mechanical trituration with a ﬁne narrowed
Pasteur pipette. After centrifugation at 800 rpm for 3 minutes,
the cells were resuspended in the same culture medium used
for human neurosphere culture (but without leukemia
inhibiting factor and heparin) and cultured in a humidiﬁed
atmosphere of 5% CO2 incubator at 37-C. Half of the
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medium was changed every 3 days. Primary neurospheres
were cultivated for 6 to 10 days before harvest.
For differentiation, 5 to 10 neurospheres were attached
onto polyornithine- and laminin-coated glass coverslips
(14-mm diameter) in a 24-well plate (Nunc, Roskilde, Den-
mark) and cultured up to 14 days with DMEM/F12 medium
containing either B27 supplement or 10% fetal bovine serum.
Anti-SMARCAL1 Antibody Production
An anti-SMARCAL1 antiserum was generated as
previously described (16). The antiserum identiﬁes a speciﬁc
antigen that is not present in patients with biallelic nonsense
mutations of SMARCAL1. It recognizes a speciﬁc band of
the appropriate molecular weight on Western blots of human
tissue extracts.
Western Blotting
The fetal human brain samples were removed at
autopsy, snap-frozen in liquid nitrogen, and stored at
j80-C; the adult human brain samples were purchased from
BD Biosciences (Franklin Lakes, NJ). Tissues were homo-
genized in 2 sodium dodecyl sulfate (SDS) sample buffer
(Invitrogen, Carlsbad, CA) and boiled for 5 minutes. Protein
(10 Kg) was loaded into each well, fractionated on a 7%
SDS-polyacrylamide gel electrophoresis gel, and transferred
to a polyvinylidene ﬂuoride membrane (Invitrogen). After
blocking with phosphate-buffered saline (PBS) containing
0.2% I-Block (Applied Biosystems, Foster City, CA) for
1 hour at room temperature (RT), a 1:5000 dilution of the
anti-SMARCAL1 rabbit polyclonal antibody and a 1:5000
dilution of anti-glyceraldehyde 3-phosphate dehydrogenase
mouse monoclonal antibody (MAB374; Chemicon) were
incubated with the membrane for 1 hour at RT. After
incubation with the primary antibodies, the Western blots
were washed with blocking buffer 3 times for 10 minutes
each at RT and then incubated with alkaline phosphatase-
conjugated secondary antibodies (anti-rabbit immunoglobulin
(Ig)G and anti-mouse IgG: A2556 and A3562, respectively;
Sigma) for 30 minutes at RT. The blots were then washed 3
times for 10 minutes each at RT. The bound antibody was
detected by chemiluminescence using CDP-Star (Applied
Biosystems) according to the manufacturer_s speciﬁcations.
Immunohistochemistry
Human and mouse brains were ﬁxed by immersion in
10% buffered formalin or 4% paraformaldehyde (PFA) in
PBS. The brain tissue was processed, embedded in parafﬁn,
and cut into 8-Km sections according to standard protocols
(17). Immunohistochemistry was done as previously
described (16). We used the following primary antibodies:
polyclonal rabbit anti-human SMARCAL1 (BCM312),
diluted 1:200; monoclonal mouse anti-rat Musashi1 (14H1
[18]), diluted 1:500; anti-human Hu (18), diluted 1:1000; and
a polyclonal anti-glial ﬁbrillary acidic protein (GFAP; Dako,
Carpinteria, CA), diluted 1:1000.
Immunoﬂuorescence
To determine the cell types in which SMARCAL1
was expressed in the human and the mouse brain, we
performed double immunoﬂuorescence using a 27YGW
human brain and mouse brains ranging in age from E8.5
to adult. The brains were ﬁxed in 4% PFA for 48 hours,
immersed in 30% sucrose for 48 hours, and then frozen
in optimal cutting temparature-embedding medium on dry
ice. After cutting 8- to 20-Km-thick sections using a
cryostat, the tissue sections were placed on Superfrost plus
microslides (VWR International, West Chester, PA) and
incubated with the primary antibodies in 10% normal horse
serum for 2 hours at RT or overnight at 4-C. The sections
were then rinsed with PBS with 0.02% Tween. For visual-
ization, we used the Alexa 568-conjugated secondary anti-
bodies anti-rat IgG, anti-rabbit IgG, and anti-human IgG, and
the Alexa 488-conjugated secondary antibodies anti-rat IgG,
anti-rabbit IgG, and anti-human IgG (Molecular Probes,
Eugene, OR). After incubation with the secondary antibodies
for 30 minutes at RT, the tissue sections were rinsed 4 times
with PBS with 0.02% Tween and mounted in Vectashield
(Vector Laboratories, Burlingame, CA).
Human and mouse neurospheres and single neural
precursor cells grown on coverslips were ﬁxed in 4% PFA in
PBS for 15 minutes at RT, washed 3 times with PBS,
permeabilized with 0.3% Triton X-100 in PBS for 5 minutes,
washed 3 times with PBS, and blocked with 5% horse serum
in 1% casein (PIERCE, Rockford, IL) for 30 minutes at RT.
Primary antibodies were diluted in 10% horse serum in PBS
and incubated with the ﬁxed cells overnight at 4-C. After
washing in PBS, secondary antibodies diluted in PBS were
incubated with the ﬁxed cells for 30 minutes at RT and
mounted in Vectashield (Vector Laboratories). Images were
acquired using a Zeiss Axiovert 200 microscope (Jena,
Germany), a Zeiss AxioCamHR (bright-ﬁeld) or a Zeiss
AxioCamMR camera (ﬂuorescence), and the Zeiss AxioVi-
sion imaging system. Confocal images were acquired as
image stacks of separate channels with a Zeiss LSM 510
microscope and combined and visualized with Zeiss LSM
Image Browser v3.2.
Reverse-Transcriptase-PolymeraseChain Reaction
Total RNA was extracted from 2 independent human
neural stem cell cultures using the RNeasy kit (Qiagen). The
RNA was reverse transcribed into cDNA using random
primers and RNase H-MMLV reverse transcriptase (Strata-
gene). Primers speciﬁc to the human SMARCAL1 cDNA
were designed and used for polymerase chain reaction (PCR)
ampliﬁcation (30 cycles of 94-C for 30 seconds, 55-C for
30 seconds, and 72-C for 1 minute). Ampliﬁcation of actin
cDNAs was used as a reference control. The primer pairs
used were 5¶-CAGGACCTTATTGCGCTTTT-3¶ and 5¶-
CGGGCAGTCCTACTGTTTTT-3¶ for human SMARCAL1
PCR and 5¶-GCTCACCATGGATGATGATATCGC-3¶ and
5¶-GGAGGAGCAATGATCTTGATCTTC-3¶ for actin. The
PCR products were run on a 2% agarose gel and detected by
ethidium bromide.
Northern Blot Analysis
Human tissue Northern blots were purchased from
Clontech (Mountain View, CA) and hybridized according to
the manufacturer_s instructions. Mouse brains (E14.5 adult)
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or heads (E9.5YE12.5) were dissected and snap-frozen in
liquid nitrogen. Total RNA was prepared using the Ambion
total RNA kit (Ambion, Austin, TX). Total RNA (20 Kg) of
each sample was loaded onto 1% agarose-formaldehyde gel
and transferred to a nylon membrane (Ambion) overnight by
capillary transfer using 20 sodium chloride-sodium citrate
(SSC). After prehybridization in hybridization buffer (15%
formamide, 40 mmol/L of NaPO4, pH 7.2, 10 mmol/L
of EDTA, 7% SDS, 2% bovine serum albumin), the ﬁlters
were hybridized with 32P-labeled cDNA probes in fresh
buffer at 65-C overnight. DNA probes for Northern hybrid-
ization were synthesized from the human or the mouse 5¶-
untranslated region of the SMARCAL1/Smarcal1 cDNA
using a random-prime labeling system (Amersham, Piscat-
away, NJ). Hybridized membranes were washed in buffer (40
mmol/L of NaPO4, 1 mmol/L of EDTA, 1% SDS) 3 times for
30 minutes each at 65-C and exposed to ﬁlm. As a control for
the amount of RNA loaded in each lane, the probe was
stripped from the membrane with 10 mmol/L of Tris-HCl, 1
mmol/L of EDTA, 0.1% SDS containing buffer at 100-C,
and the membrane was rehybridized with a glyceraldehyde
3-phosphate dehydrogenase probe.
In Situ Hybridization
Digoxigenin-labeled mouse Smarcal1 antisense and
sense riboprobes were synthesized using an in vitro tran-
scription kit (Roche, Indianapolis, IN) according the instruc-
tions. The fresh brain sections were sectioned at 10 Km.
Sections were ﬁxed in 4% PFA for 20 minutes and washed
twice in 1 PBS, treated with 0.1 N of HCl for 20 minutes,
digested with proteinase K in 1 TE at 37-C for 10 minutes,
washed once in deionized water, postﬁxed with 4% PFA for
20 minutes, then incubated in 0.25% acetic anhydride/0.1
mol/L of triethanolamine (pH 8.0) for 10 minutes. After a
brief wash with 2 SSC, the sections were prehybridized for
1 hour at 55-C in the hybridization buffer containing 50%
deionized formamide, 0.2% SDS, 0.75 mol/L of NaCl, 25
mmol/L of piperazine diethanesulfonic acid, 25 mmol/L of
Tris-HCl and EDTA, 1 Denhardt and 50 Kg/ml of salmon
sperm DNA, and hybridized in the same buffer containing 1
Kg/ml of either antisense or sense Smarcal1 probe at 55-C
overnight. After hybridization, the sections were rinsed
brieﬂy in 4 SSC at 55-C 5 times for each 5 minutes and
2 SSC for 30 minutes at 55-C. After a 10-minute wash with
RNase buffer containing 10 mmol/L of Tris-HCl and 0.5
mol/L of NaCl, the unbound RNA probes were digested with
20 Kg/ml of RNase A in the same buffer for 30 minutes at
37-C. The sections were then washed 2 times in 0.1 SSC
for 15 minutes at RT. After several rinses in Tris-buffered
saline (0.15 mol/L of NaCl, 0.1 mol/L of Tris, pH 7.5), the
sections were incubated in 0.5% blocking solution (Roche)
for 30 minutes at RT, followed by incubation for 2 hours
with alkaline phosphatase-conjugated sheep anti-digoxigenin
antibody (1:1000; Roche) at RT. After several washes with
50 mmol/L of MgCl2 in Tris-buffered saline, pH 9.5, the
phosphatase reaction was performed using nitroblue tetrazo-
lium-5-bromo-4-chloro-3-indolylphosphate as substrates. The
color reaction was developed in the dark until satisfying
results were obtained.
RESULTS
Neurodevelopment of SIOD Patients
To ascertain whether SIOD patients have neurologic
abnormalities, we sent questionnaires to the physicians of
38 SIOD patients with identiﬁed SMARCAL1 mutations
and received 33 responses (Table 1). Half of the patients
had a head circumference less than the third percentile. We
did not detect a signiﬁcant correlation of head circumference
with disease severity as scored using our previously
deﬁned scale (19) or with age at death (Figs. 1A, B). Stature
was neither predictive of head circumference nor was the
head circumference always disproportionately larger or
smaller (Fig. 1C); nearly half had disproportionately large
or small heads, and of these, half were larger and half were
smaller. To date, imaging studies have not identiﬁed
structural abnormalities indicating a cause of abnormal head
growth (16).
We also compared head circumference to the different
patient mutations to determine whether the SMARCAL1
mutations were predictive of head circumference. Among
patients with a sequence variant encoding a nonsense,
frameshift, or deletion mutation on both alleles, 60% had a
head circumference less than the third percentile; among
patients with a sequence variant encoding a nonsense,
frameshift, or deletion mutation on 1 allele and a sequence
variant encoding a missense mutation on the other allele,
57% had a head circumference less than the third percentile;
and among patients with sequence variants encoding mis-
sense mutations on both alleles, 44% had a head circum-
ference less than the third percentile (Fig. 1D). These
observations suggest a trend toward preserved brain growth
in the background of biallelic missense mutations, but the
number of patients is too small for this to be statistically
signiﬁcant.
As assessed by their primary care physicians, 5 of the
33 patients had mild delay of 1 or more developmental
parameter; only 1 patient (Patient 57), who had a stroke at 4
years of age, had warranted formal developmental testing and
required intervention services (20). Of the 26 patients who
attended school, 22 had normal school performance. All
patients with a disproportionately large head circumference
(Patients 16, 28, 30, 33a, 39, 44, 47, and 51) had normal
development, whereas 1 (Patient 27) of 6 patients (Patients
23, 27, 45, 49, 60, and 71) with a disproportionately small
head circumference did not. The mutation type was not
predictive of a disproportionately small or large head size or
of the developmental pattern. Several patients had electro-
encephalographic (EEG) abnormalities such as excessive
background slowing and foci of rhythmic and arrhythmic
slowing, but only 2 patients manifested clinical seizures prior
to the onset of cerebral ischemia (Table 1).
SMARCAL1 Expression During Human and
Mouse CNS Development
The ﬁndings of frequent microcephaly and EEG
abnormalities among SIOD patients prior to their manifes-
tation of cerebral ischemia suggested that SMARCAL1 may
play an autonomous role in neurodevelopment. Therefore, we
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TABLE 1. Clinical Features of 33 Patients with SIOD and SMARCAL1 Mutations
Patient
(mutation [19])
OFC
Percentile
Height
Percentile
Disease
Severity
Score*
(maximum
= 5) Delay
Physician_s Assessment of
Developmental Delay
School
Performance Seizure
EEG
Abnormality
Memory
Problem
Mood
Problem
Age, years
Motor Language Social Intellect Death Current
Survival G 20 years
33a
(c.1146_1147delAA+
c.1147+
1_2delGT, c.1097-2A9G)
3Y10 G3 3 No N/A UA UA 2.75
50 (c.2542G9T) G3 G3 3 No Normal Yes§ Yes No No 8
53 (c.2291G9A,
c.2542G9T)
50 50 3 No Normal UA UA 13.5
8 (c.1190delT) G3 G3 4 No N/A UA UA UA UA 5.7
23 (c.2542G9T) G3 3Y10 4 No N/A‡ No No 10.25
28 (c.1702delG) 50 3Y10 4 No Normal No No No No 12
31 (Del ex1-4) G3 G3 4 No Normal No No 14
35 (c.1736C9T,
c.2321C9A)
G3† G3 4 No Normal No No 8
47 (c.2459G9A) 25Y50 G3 4 No Normal No No 16.6
48 (c.1939A9C) G3 3 4 Yes Mild
delay
Mild
delay
Mild
delay
Mild
delay
N/A No No No No 6
49 (c.1920_1921insG) G3 10 4 No Normal UA UA 4.8
60 (c.2542G9T) G3 25 4 No Normal No No 13.6
61 (c.1146_1147delAA+
c.1147+1_2delGT)
UA G3 4 No N/A No No 5
66 (c.1933 C9T) G3† G3§ 4 No Normal No No 13
68 (c.1940 A9C, c.2462
T9G)
3Y10 3Y10 4 No Normal Yes Yes 7.1
72 (c.836T9C,
c.1136A9C)
G3 G3 4 No Normal Yes Yes Yes 9.6
74 (c.1736C9T) 10Y25 10Y25 4 No N/A No No 7.5
24 (Del ex1-4) G3† G3† 5 Yes Mild
delay
Mild
delay
Mild
delay
Mild delay Yesk Yes No No 9
25 (c.49C9T, c.100C9T) 50† UA 5 No Normal Yesk No No 10.1
29 (c. 1934delG,
c.862+1G9T)
G3 G3 5 Yes N/A UA UA 4
30 (c.1132G9T) 10Y25 G3 5 No Normal No No 10
38 (c.1096+1G9A) G3 G3 5 Yes Mild
delay
Mild
delay
Normal No Yes No No 10.75
39 (c.1402G9C,
c.2114C9T)
10Y25† 10 5 No Normal Yes¶ Yes No Yes 15
44 (c.1191delG,
c.2321C9A)
3Y10 3 5 No Normal UA UA 11.9
51 (c.2542G9T,
c.2459G9A)
25 G3 5 No Normal No Yes No No 12
71 (c.836T9C, c.1000C9T) G3 3Y10 5 No Normal Yes No 10.8
Survival Q 20 years
65a (c.836T9C,
c.2542G9T)
90 75 1 No Normal No No 26.9
27 (c.1940A9C) G3 3Y10 2 Yes Mild
delay
Mild delay No No 25.6
45 (c.1874C9G,
c.2459G9A)
G3 25 2 No Normal UA UA 28.1
65b (c.836T9C,
c.2542G9T)
25 25 3 No Normal Yes No 24
16 (c.1643T9A,
c.1933C9T)
50† G3 3 No Normal No No 32
57 (c.955 C9T) 3Y10 3Y10 4 Yes Mild
delay
Moderate
delay
Mild
delay
Mild
delay
Moderate
delay
Yesk Yes Yes Yes 25.9
84 (c.1248_1249insC,
c.2104T9G)
G3† G3 5 No Normal No No 23
*, Point system reﬂecting the severity of symptoms associated with SIOD: linear growth failure before 10 years of age received 1 point; renal failure received 1 point;
lymphopenia received 1 point; recurrent infections received 1 point; cerebral ischemia received 1 point (19).
†, Percentile at ﬁrst clinic visit with reporting physician. For all others, the percentile at birth is given.
‡, Patient had a severe stroke prior to beginning school and was never able to attend mainstream schools.
§, One generalized seizure at 3 years, apparently unrelated to cerebral ischemic events.
k, Seizures started after the onset of cerebral ischemic events.
¶, One generalized seizure at 13 years, apparently unrelated to cerebral ischemic events.
N/A, not applicable; OFC, occipital-frontal circumference; SIOD, Schimke immuno-osseous dysplasia; UA, unavailable.
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hypothesized that SMARCAL1 would be expressed in the
mouse and human nervous system and proﬁled its expression
in the developing and mature mouse and human CNS. In the
mammalian brain, the Layer I Cajal-Retzius neurons are the
ﬁrst neurons to mature. Other cortical neurons are generated
from neural stem cells in the neuroectoderm surrounding the
ventricles, that is, the ventricular zone (VZ) and subven-
tricular zone (SVZ), and migrate to form the cortex.
Astrocytes and oligodendrocytes also arise from the stem
cells in the VZ and SVZ. As the brain matures, the VZ and
SVZ retain a small number of neural precursors (21).
As each cell type migrates away from the VZ and SVZ,
it differentiates, and this maturation can be detected by
expression of speciﬁc proteins. The markers followed were as
follows: 1) Musashi1 and Nestin, which are markers of neural
precursors, immature neurons, and immature astrocytes (18,
22Y24); 2) Hu, which is a marker of postmitotic immature
and mature neurons (25); 3) GFAP, which is a marker of
immature and mature astrocytes (26); and 4) O4 and 2¶,3¶-
cyclic-nucleotide 3¶-phosphodiesterase, which are markers of
immature and mature oligodendroglia (27, 28).
As assessed by Northern (Fig. 2A) and Western (Fig. 2B)
blots, in situ hybridization (Figs. 2CYL), and immunohisto-
chemistry (Figs. 2MYP), we demonstrated that Smarcal1 is
expressed in the developing and mature mouse brain. In the
embryo, Smarcal1 was strongly expressed in the VZ, SVZ,
intermediate zone, and cortical plate (data not shown). In
postnatal brains, we observed Smarcal1 expression in the VZ
and SVZ, as well as in cortical, cerebellar, spinal, and peripheral
neurons (Figs. 2CYP).
By immunoﬂuorescent colocalization studies in the
adult mouse brain, we observed cortical colocalization of
Smarcal1 with the neuronal marker Hu in postmitotic
neurons (Figs. 3AYD), but not with GFAP in mature
astrocytes (Figs. 3EYH). In the ependyma and the VZ and
SVZ, Smarcal1 colocalized with the precursor cell marker
Musashi1 (Figs. 3IYL) and with GFAP in a few SVZ cells
(data not shown). We also conﬁrmed expression of Smarcal1
in cultured mouse neural precursors by immunoﬂuorescence
(Figs. 3MYR) and Western blot (Fig. 3S) analyses of mouse
neurospheres.
We next determined the cell type-speciﬁc temporal and
spatial distribution of SMARCAL1 in the human brain by
Western blot analysis (Figs. 4A, B) and by immunohisto-
chemistry (Figs. 4CYI). We performed immunohistochemis-
try on 40 human brains ranging in age from 10 GW to 61
FIGURE 1. Analysis of SIOD patient head circumferences. (A) Comparison of head circumference to disease severity. (B)
Comparison of head circumference to age of death. (C) Comparison of head circumference to stature. (D) Comparison of head
circumference to predicted SMARCAL1 mutation. M, a sequence variant encoding a missense mutation; N, a sequence variant
encoding a nonsense, frameshift, or deletion mutation.
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years (23 prenatal and 17 postnatal). In prenatal brains, there
was strong nuclear expression of SMARCAL1 in most cells
of the immature cortex, in some cells within VZ and SVZ,
and along the migratory pathway from the VZ/SVZ to the
cortex (Fig. 4C).
Among the 17 postnatal brains (newborn to 61 years
old), SMARCAL1 was expressed in the nuclei of a subset
of cells in the SVZ and in a subset of cortical neurons
(Figs. 4DYF). Expression in cells in the white matter
decreased with age (data not shown). SMARCAL1 continued
to be expressed predominantly in the nuclei of cortical
neurons in the postnatal brains (Figs. 4DYF), although at a
lower staining intensity than in the fetal brain. Expression in
human neural precursors was conﬁrmed by immunoﬂuores-
cent (Fig. 4JYL) and reverse-transcriptase-PCR (Fig. 4M)
analyses of cultured human neurospheres.
Neuropathology of SIOD Patients
The clinical observations of frequent small head circum-
ference and EEG abnormalities in SIOD patients and the
FIGURE 2. Northern blot, Western blot, in situ hybridization, and immunohistochemical analyses of Smarcal1 expression in the
murine brain. (A) Northern analysis for Smarcal1 mRNA expression in the developing mouse brain. Each lane contained 20 Kg of
total RNA. For samples E9.5 to E12.5, the RNA was derived from whole head extracts. For samples E14.5 to adult, the RNA was
derived from isolated brains. (B) Western analysis for Smarcal1 expression in protein extracts from the whole mouse brains from
developmental stages E12.5, E14.5, E17.5, P0, P7, and adult. Panel shows a single Smarcal1 protein band despite detection of 2
mRNA bands on the Northern shown in (A). The membrane was concurrently probed for glyceraldehyde 3-phosphate
dehydrogenase expression to control for protein integrity and loading. (CYL) In situ hybridization detection of Smarcal1
expression in the P0 cerebrum (C), in the P7 cortex (D), P7 hippocampus (E), P7 cerebellum (F), P7 spinal cord, and P7 dorsal
root ganglia (G), and in the adult cortex (H), adult hippocampus (I), adult cerebellum (J), and adult spinal cord (K). (L) Panel
shows hybridization of the sense control probe to a serial section of adult cortex. (MYP) Immunohistochemical detection of
Smarcal1 protein expression in the adult spinal cord (M), dorsal root ganglion (N), cerebellum (O), and cortex (P). The upper inset in
(M) is a higher magniﬁcation of the dorsal horn, and the lower inset is a higher magniﬁcation of the anterior horn. The inset in (P) is a
higher magniﬁcation of cortical Layer II. Bar = 50 Km. AH, anterior horn; DH, dorsal horn; DRG, dorsal root ganglion; E, embryonic day;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GL, granular layer; ML, molecular layer; P, postnatal day; PC, Purkinje cell.
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expression of SMARCAL1 during brain development suggest
that deﬁciency of SMARCAL1 may cause defective neuro-
development. To investigate this possibility, we examined
available microscopic sections of brain tissue on Patient SD60,
who died of cardiopulmonary arrest at the age of 13 years (10),
and Patient SD 84, who died of pulmonary hypertension and
right heart failure at the age of 23 years (21). Both had had a
head circumference of less than the third percentile and
normal language, social, motor, and cognitive development.
They had excelled academically, as is usual for SIOD patients
prior to the onset of cerebral ischemic attacks, and they did
not have a seizure disorder. The neuropathologic examination
in these cases is regrettably incomplete. Vascular pathology
was observed and was previously reported based on our
initial observations of several microscopic slides that were
available from autopsy material (10). Upon request, addi-
tional microscopic slides and some parafﬁn blocks were
kindly sent to us by referring institutions; however, not all
regions were sampled or identiﬁed. Despite these limitations,
we studied the available materials and report our interpreta-
tions for comparison to more complete analyses.
Because of the limited samples available, the following
observations cannot be considered conclusive or complete.
Rather, they are to serve as a basis for future studies.
According to the autopsy reports, the brains of Patients SD60
and SD84 weighed less than normal and had areas of
infarction and ischemia (Table 2). Despite normal CNS
function and antemortem brain magnetic resonance imaging,
the nonischemic areas of both brains had very subtle, but
consistent, histologic abnormalities. In several focal regions
of cerebellar folia, the Purkinje cells (as deﬁned by serial
sectioning) seemed to be poorly aligned (Supplemental
Fig. 2A); however, because of incomplete materials, the
vermis, which has been reported as abnormal by magnetic
resonance imaging in some SIOD patients (29), could not
be assessed. In the cerebral cortex and the subcortical
white matter, focal structural anomalies were observed in
50% of the available cortical sections. The microscopic
FIGURE 3. Immunoﬂuorescent characterization of Smarcal1 expression in an adult mouse brain. Smarcal1 colocalizes with Hu
(AYD) but not with glial ﬁbrillary acidic protein (EYH) in the cortex, and with Musashi1 in the ventricular zone and subventricular
zone (IYL). As detected by immunoﬂuorescence (MYR) and Western blot (S), Smarcal1 is also expressed in cultured neurospheres
(MYO) and in the individual cells dissociated from the neurospheres (PYR). The negative control for the Western blot is an extract
from lymphoblastoid cells from a patient homozygous for deletion of the SMARCAL1 gene promoter and ﬁrst 4 exons. Bar = 50
Km. cnt, control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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malformations included subcortical Bheterotopias,[ some of
which were veriﬁed by serial sectioning to be separate from
the cortex and not related to tangential sectioning (Supple-
mental Fig. 2B). Upon serial sectioning, some of the
heterotopias (Supplemental Fig. 2B; marked with a star)
represented an extension of the Bexpanded cortex[ as
described in the succeeding sentences. Within these areas,
no organization of neurons could be discerned. There were
also isolated sections of expanded cortex. For example, the
cortical thickness in temporal cortex of SD84 ranged from
2.0 to 6.0 mm, whereas in an age-matched control, the same
regions measured 1.5 to 4.5 mm. In the Bthicker[ regions of
cortex, there were usually several other associated ﬁndings.
There was a loss of a well-deﬁned Layer II in each section
examined (Supplemental Fig. 2C) as deﬁned by calbindin
immunoreactivity, which is normally present in only Layer II
neurons (control frontal cortex; Supplemental Fig. 2D). There
was poor deﬁnition of the cortical gray-white matter junction
similar to that observed in cortical dysplasia. In addition, near
the expanded cortex, serial sections frequently revealed a
failure of separation of gyri and aberrant deﬁnition of sulci
(data not shown). Importantly, the malformations were
FIGURE 4. Western blot and immunohistochemical analyses of SMARCAL1 protein expression in the human brain. (A) Western
analysis for SMARCAL1 expression in protein extracts from whole human brain at 6, 8, and 10 gestational weeks (GW); the brain is
predominantly neural precursors at 6 weeks of gestation. The membrane was concurrently probed for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression to control for protein integrity and loading. (B) Western analysis for SMARCAL1
expression in protein extracts from the cortex (cx), cerebellum (cb), and hippocampus (hp) of the adult human brain. The
membrane was concurrently probed for GAPDH expression to control for protein integrity and loading. (C) SMARCAL1 expression
in the cerebrum of a human 10-GW brain. Cells in the ventricular zone (VZ), subventricular zone (SVZ), IMZ, and the CP express
SMARCAL1. Higher-magniﬁcation image of SMARCAL1 expression in the CP of the human 10-GW brain (upper inset). Higher-
magniﬁcation image of SMARCAL1 expression in the VZ and SVZ of the human 10-GW brain (lower inset). (D, E) Expression of
SMARCAL1 in the cortex and ependyma of a 40-GW brain. The inset (D) shows SMARCAL1 expression in cortical Layer II. (F)
Expression of SMARCAL1 in adult cortical neurons. The inset shows SMARCAL1 expression in cortical Layer II. (GYI) Serial sections
treated with preimmune serum. As detected by immunoﬂuorescence (JYL) and reverse-transcriptase-polymerase chain reaction
(M), SMARCAL1 is also expressed in cultured neurospheres. Bar = 50 Km. cnt, control; CP, cortical plate; IMZ, intermediate zone;
V, ventricle.
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microscopic and required serial sectioning to assess their
positions within the cortex. Probably only a powerful and
detailed imaging system could have identiﬁed them in the
living patient.
Because of the role of SMARCAL1 in cell proliferation
and its presence in neural precursor cells (and because of the
ﬁndings in the SIOD cases), we questioned whether neural
precursor cells can be identiﬁed in subventricular regions in
the brain tissue samples. Using the markers Mushashi-1 and
Nestin (30), we detected neural precursor cells, indicating
that there was not a complete absence of these neural
precursor cells in these small brains (Supplemental Figs.
3AYL). There were, however, fewer of them than in the
control brain sample (Supplemental Fig. 3P).
Knockdown Studies in Mouse Neurospheres
Based on the suggestion that deﬁciency of SMAR-
CAL1 contributes to a reduced number of precursors, we
performed siRNA knockdown of Smarcal1 in mouse neuro-
spheres. The results indicated that the neurospheres grow less
well when they were made deﬁcient in Smarcal1 (Supple-
mental Figs. 3QYU). Using 2 different siRNA oligonucleo-
tides for Smarcal1 neurospheres derived from ICR and 129
SvEv mice, 3 independent experiments for each condition
showed 53% to 67% transfection efﬁciency and, as measured
by Western blot, a 40% to 50% knockdown of SMARCAL1
protein 4 days after transfection (Supplemental Fig. 3V).
Four days after transfection with the Smarcal1 siRNA, the
number and radii of neurospheres as well as the number of
cells per neurosphere were signiﬁcantly reduced (p G 0.001),
whereas cells transfected with the control siRNA were
unaffected (Supplemental Figs. 3QYU). Therefore, although
deﬁciency for SMARCAL1 does not cause a complete loss of
neural precursors, it may be one factor contributing to the
small brain size in these patients. These results require
conﬁrmation both when there are additional studies on SIOD
patient tissues and when Smarcal1 knockout mice become
available.
DISCUSSION
SMARCAL1 is a unique member of the SNF2 family
of chromatin remodeling proteins that have DNA-dependent
adenosine triphosphatase activity (12, 31). We recently
determined that mutations of SMARCAL1 cause SIOD (9).
In this report, we show for the ﬁrst time that 1) there is
expression of SMARCAL1 in CNS neurons and neural
precursors in both humans and mice; 2) SIOD patients often
have a reduced head circumference (microcephaly); and 3)
autopsy observations of 2 male SIOD patients identify subtle
histologic features suggestive of perturbed neuron-glial
migration that warrant conﬁrmation and detailed examination
in future autopsy studies of SIOD.
The microcephaly is consistent with our previous
hypothesis that SMARCAL1 expression facilitates cellular
proliferation (9, 10, 19). The head circumference measure-
ments were obtained at birth or prior to the onset of cerebral
ischemia, which contributes to reduced brain weight and the
acquired cerebellar atrophy reported in some SIOD patients
(29). Surprisingly, the microcephaly did not correlate with
other clinical features, and despite microcephaly and the
subtle histologic features suggestive of perturbed neuron-glial
migration, most SIOD patients had generally normal social,
language, motor, and cognitive development, and very few
had seizures (Table 1). These observations suggest that
SMARCAL1 participates in the modulation of both neural
proliferation and differentiation but that the morphologic
abnormalities that result from deﬁciency of SMARCAL1
rarely cause serious neurophysiologic dysfunction or devel-
opmental deﬁcits. Examination of the brains from SIOD
patients who manifest abnormal development or seizures
would, however, clarify the range of CNS abnormalities
associated with SMARCAL1 deﬁciency.
TABLE 2. Summary of Brain Pathologic Findings in SIOD Patients SD60 and SD84
SIOD Patient
SD60 SD84
Gross pathology
Brain weight 1,100 g (normal, 1,300 g) 1,020 g (normal, 1,300Y1,400 g)
Blood vessels* Abnormal Abnormal
Cerebrum Normal gross structure, diffuse ischemic changes Normal gross structure, recent and old focal infarcts
Cerebellum Normal gross appearance, possible focal Purkinje
cell crowding
Normal gross appearance, possible focal Purkinje
cell crowding
Brainstem Normal Normal
Cortical pathology
Focal cortical expansion 4/9† 10/24†
Subcortical heterotopia 1/9† 4/24†
Incomplete sulcation 3/9† 5/24†
Displaced Layer II 2/2‡ 3/3‡
*, The blood vessel pathology is described in Reference 10.
†, The denominator is the number of cortical sections available, and the numerator is the number of these sections with the observed alteration.
‡, The denominator is the number of cortical sections stained with anti-calbindin, and the numerator is the number of these sections with the abnormal localization of calbindin-
positive neurons.
SIOD, Schimke immuno-osseous dysplasia.
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The lack of overt functional CNS deﬁcits in most SIOD
patients contrasts with the severe neurologic deﬁcits observed
with deﬁciency of the SNF2 factor >-thalassemia mental
retardation, X-linked syndrome (32). Individuals with pri-
mary microcephaly may, however, have minimal neurologic
problems (33Y35). Unlike many other skeletal dysplasias
and genetic disorders of generalized growth, the relationship
between stature and head circumference is not uniform
in SIOD. This suggests that loss of SMARCAL1 function
is not sufﬁcient for the development of microcephaly, and
that stochastic, epigenetic, environmental, or other genetic
factors might also contribute to the microcephaly in SIOD
patients.
Poor brain growth can result from a reduction in cell
number or size but generally has been ascribed to a reduction
in cell number (36). Such a reduction can arise either from
reduced proliferation or from increased death of glia and/or
neurons (37). Based on the spatio-temporal expression of
SMARCAL1/Smarcal1 in the human brain, SMARCAL1
deﬁciency might affect neural precursor viability from early
in embryogenesis to postnatal life, thereby contributing to
the decreased mean prenatal and postnatal head circum-
ferences observed in many of the patients with SIOD.
Moreover, the early-onset cognitive impairment that we have
observed in some adult SIOD patients might be attributable
to a failure of ongoing neurogenesis in addition to the
cerebrovascular disease that results in stroke-like episodes
(10, 29, 38, 39).
In addition to the modulation of numbers of neural
precursor cells, our ﬁndings also implicate SMARCAL1 in
the regulation of neuronal migration and cortical differ-
entiation. The presence of microscopic periventricular heter-
otopia, cortical microdysgenesis, and aberrant gyration seen
in both autopsy cases have been observed in other disorders
of neural migration and cortical patterning (40). Cortical
microdysgenesis has been associated with infantile spasms
(41), primary generalized epilepsy (42), partial epilepsy (43),
dyslexia (44, 45), congenital mental retardation (46), and
autism-like disorders (46). Although neither of the autopsy
cases we studied was associated with these disorders,
histories of the clinical cohort did reveal some of these
conditions: 2 SIOD patients had seizures, 7 had EEG
changes, and there was mild mental delay in 7. These clinical
features in SIOD patients warrant careful examination for
evidence of histologic correlates that may suggest perturbed
neuron-glial migration. It might also be worth considering
whether SIOD patients, who have generally intractable
migraine-like headaches, might also be manifesting a partial
seizure disorder (16, 47).
The histologic features suggestive of perturbed neuron-
glial migration identiﬁed would arise from a disturbance in
the later stages of radial neuronal migration and cortical
organization, whereas heterotopias would arise as a disturb-
ance of the earlier stages of radial neuronal migration. The
molecular basis of the cortical microdysgenesis in neurologic
disorders is undeﬁned, although some have suggested
aberrant secretion of reelin by Cajal-Retzius neurons (48).
We found expression of SMARCAL1 in the migrating
neuronal precursors, cortical neurons, and in the Cajal-
Retzius neurons, but not in cortical oligodendrocytes or
astrocytes (Fig. 5). Based on our prior studies suggesting a
cell-autonomous function for SMARCAL1 (10, 49, 50), we
FIGURE 5. Schematic of SMARCAL1/Smarcal1 expression during brain development. (A) In normal developing brain,
SMARCAL1 is present in cells of neuronal lineage, including neural precursor cells, migrating immature neurons, and
postmigrating neurons in cortex. (B) SMARCAL1 expression remains both in the adult neural stem cells in ventricular zone/
subventricular zone and mature cortical neurons. (C) When SMARCAL1 is deﬁcient, the brain is smaller than normal, possibly
because the numbers of adult stem cells may be reduced. Potential impairment in neuronal migration and cortical differentiation
can result in histologic features suggestive of lesions such as microdysgenesis and abnormal cortical layering.
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hypothesize that the cortical malformations can arise as a
consequence of SMARCAL1 dysfunction within the neuro-
nal lineage.
As a member of the swi/snf class of enzymes,
SMARCAL1 might alter chromatin structure and/or expres-
sion of genes necessary for neural precursor viability or
proliferation as well as for effective neuronal migration.
Involvement of chromatin remodeling factors in neural
precursor renewal has been observed for the mammalian
Polycomb group enzyme Bmi-1 (51, 52) and for the Brm-/
Brg-1-associated complexes (53Y55). Brm-/Brg-1-associated
complexes also modulate glial and neuronal differentiation.
The murine SWI/SNF (BAF) subunits have nonredundant
and dosage-sensitive roles in neural development. Indeed,
mice heterozygous for either Brg or BAF155/Srg3 are
predisposed to exencephaly (54, 55), and Brg is essential
for the repression of neuronal commitment in neural stem
cells (56). Furthermore, the transition from proliferating
neural stem/progenitor cells to postmitotic neurons requires
a switch in subunit composition of the Brm-/Brg-1-associated
complexes (53). We postulate that SMARCAL1/Smarcal1
might be a member of other chromatin remodeling complexes
that similarly regulate the expression of genes necessary for
neural precursor viability and/or renewal as well as for
neuronal migration and cortical differentiation. Thus, deﬁ-
ciency of SMARCAL1 would result in a paucity of neural
precursors, abnormalities of neuronal migration, and cortical
malformations.
A role for SMARCAL1/Smarcal1 in modulating pre-
cursor cell renewal and differentiation can also explain the
hematopoiesis defects observed in some SIOD patients (9, 10).
If SMARCAL1 promotes viability by inhibiting apoptosis of
bone marrow stem cells and inﬂuences their differentiation
along various lineages, this might explain the stem cell
factor-resistant bone marrow failure and the high prevalence
of T-cell immunodeﬁciency among SIOD patients (9).
In summary, we have shown for the ﬁrst time that the
disruption of SMARCAL1 expression in patients with SIOD
can result in a small brain size, minimal cortical dysgenesis,
and other subtle histologic features suggestive of perturbed
neuron-glial migration that are often not detected by clinical
and magnetic resonance imaging studies. In view of its
similarity to other chromatin remodeling proteins, we
propose that SMARCAL1 might act as a chromatin chaper-
one and thereby modulate the expression of a subset of genes
involved in neural development.
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